Management of progressive pulmonary fibrosis associated with connective tissue disease

References

• Atzeni F, Gerardi MC, Barilaro G, et al. Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. Expert Rev Clin Immunol. 2018 Jan;14(1):69–82.
   PubMed Web of Science ®Google Scholar
• Perelas A, Silver RM, Arrossi AV, et al. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020 Mar;8(3):304–320.
   PubMed Web of Science ®Google Scholar
• Castelino FV, Dellaripa PF. Recent progress in systemic sclerosis-interstitial lung disease. Curr Opin Rheumatol. 2018 Nov;30(6):570–575.
   PubMed Web of Science ®Google Scholar
• Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021 Jun;30;30(160):210011.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Lee JS, Sverzellati N, et al. The lung in rheumatoid arthritis: focus on interstitial lung disease. Arthritis Rheumatol. 2018 Oct;70(10):1544–1554.
   PubMed Web of Science ®Google Scholar
• Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.
   PubMed Web of Science ®Google Scholar
• Selva-O’Callaghan A, Pinal-Fernández I, Trallero-Araguas E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol. 2018 Sep;17(9):816–828.
   PubMed Web of Science ®Google Scholar
• Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum. 2021 Feb;51(1):72–83.
   PubMed Web of Science ®Google Scholar
• Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med. 2019 Apr;40(2):255–270.
   PubMed Web of Science ®Google Scholar
• Lee CT, Strek ME. The other connective tissue disease-associated interstitial lung diseases: sjogren’s syndrome, mixed connective tissue disease, and systemic lupus erythematosus. Curr Opin Pulm Med. 2021 Sep 1;27(5):388–395.
   PubMed Web of Science ®Google Scholar
• Narváez J, Borrell H, Sánchez-Alonso F, et al. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. Arthritis Res Ther. 2018 Dec 19;20(1):280.
   PubMedGoogle Scholar
• Sebastiani M, Manfredi A, Vacchi C, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. Clin Exp Rheumatol. 2020Mar-Apr; 124(2):221–231. 38 Suppl
   Google Scholar
• Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021 Feb;80(2):143–150.
   PubMed Web of Science ®Google Scholar
• Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev. 2015 Sep;24(137):411–419.
   PubMedGoogle Scholar
• Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014 Aug;66(8):1967–1978.
   PubMed Web of Science ®Google Scholar
• Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2017 May;29(3):254–259.
   PubMed Web of Science ®Google Scholar
• Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020 Sep 3;383(10):958–968.
   PubMed Web of Science ®Google Scholar
• Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of interferon- and transforming growth factor beta-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014 Mar;66(3):714–725.
   PubMed Web of Science ®Google Scholar
• Zhu J, Tu S, Qu Q. lncRNA BZRAP1-AS1 alleviates rheumatoid arthritis by regulating miR-1286/COL5A2 axis. Immun Inflamm Dis. 2022 Feb;10(2):163–174.
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021 Feb;80(2):219–227.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017 Mar 1;56(3):344–350.
   PubMed Web of Science ®Google Scholar
• Hyldgaard C, Ellingsen T, Hilberg O, et al. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration. 2019;98(5):455–460.
   PubMed Web of Science ®Google Scholar
• Olson A, Hartmann N, Patnaik P, et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv Ther. 2021 Feb;38(2):854–867.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014 Oct 15;190(8):906–913.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Manali ED, Kolilekas L, et al. Acute respiratory events in connective tissue disorders. Respiration. 2016;91(3):181–201.
   PubMed Web of Science ®Google Scholar
• Thomas K, Lazarini A, Kaltsonoudis E, et al. Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis. Rheumatology (Oxford). 2021 May 14;60(5):2223–2230.
   PubMed Web of Science ®Google Scholar
• Izumi Y, Akazawa M, Akeda Y, et al. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther. 2017 Jan 25;19(1):15.
   PubMed Web of Science ®Google Scholar
• Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 31;27(150):180076.
   PubMed Web of Science ®Google Scholar
• Wells A, Devaraj A, Renzoni EA, et al. Multidisciplinary evaluation in patients with lung disease associated with connective tissue disease. Semin Respir Crit Care Med. 2019 Apr;40(2):184–193.
   PubMed Web of Science ®Google Scholar
• Sebastiani M, Faverio P, Manfredi A, et al. Interstitial pneumonia with autoimmune features: why rheumatologist-pulmonologist collaboration is essential. Biomedicines. 2020 Dec 26;9(1):17.
   PubMed Web of Science ®Google Scholar
• Geerts S, Wuyts W, Langhe E, et al. Connective tissue disease associated interstitial pneumonia: a challenge for both rheumatologists and pulmonologists. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(4):326–335.
   PubMed Web of Science ®Google Scholar
• Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016 Feb 24;352:h6819
   PubMed Web of Science ®Google Scholar
• De Sadeleer LJ, Meert C, Yserbyt J, et al. Diagnostic ability of a dynamic multidisciplinary discussion in interstitial lung diseases: a retrospective observational study of 938 cases. Chest. 2018 Jun;153(6):1416–1423.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013 Sep;42(3):750–757.
   PubMed Web of Science ®Google Scholar
• Fischer A, Antoniou KM, Brown KK, et al. An official European respiratory society/American thoracic society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015 Oct;46(4):976–987.
   PubMed Web of Science ®Google Scholar
• Cano-Jiménez E, Vázquez Rodríguez T, Martín-Robles I, et al. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep. 2021 Apr 28;11(1):9184.
   PubMed Web of Science ®Google Scholar
• Robles-Pérez A, Luburich P, Bolivar S, et al. A prospective study of lung disease in a cohort of early rheumatoid arthritis patients. Sci Rep. 2020 Sep 24;10(1):15640.
   PubMedGoogle Scholar
• Sgalla G, Walsh SLF, Sverzellati N, et al. “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease. BMC Pulm Med. 2018 Jun 18;18(1):103.
   PubMedGoogle Scholar
• Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021 Nov;59(6):709–740.
   PubMed Web of Science ®Google Scholar
• Giménez Palleiro A, Franquet T. Radiological patterns in interstitial lung disease. Semin Fund Esp Reumatol. 2013;14(4):97–105.
   Google Scholar
• Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database. Ann Rheum Dis. 2010 Oct;69(10):1809–1815.
   PubMed Web of Science ®Google Scholar
• Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581–1586.
   PubMed Web of Science ®Google Scholar
• Suliman YA, Dobrota R, Huscher D, et al. Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol. 2015 Dec;67(12):3256–3261.
   PubMed Web of Science ®Google Scholar
• Narváez J, Aburto M, Seoane-Mato D, et al. Criterios de cribado de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide: propuesta de expertos basada en metodología Delphi. Reumatol Clin. 2022. [en prensa].
   Google Scholar
• Hyldgaard C, Hilberg O, Pedersen AB, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis. 2017 Oct;76(10):1700–1706.
   PubMed Web of Science ®Google Scholar
• Gizinski AM, Mascolo M, Loucks JL, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009 May;28(5):611–613.
   PubMed Web of Science ®Google Scholar
• Singh K, Al-Sadawi M, Ortega RR, et al. Interstitial lung disease as the initial manifestation of rheumatoid arthritis: a case report and review of the literature. Am J Med Case Rep. 2019;7(12):342–347.
   Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wang LS, Wei YR, et al. Clinical characteristics of connective tissue disease-associated interstitial lung disease in 1,044 Chinese patients. Chest. 2016 Jan;149(1):201–208.
   PubMed Web of Science ®Google Scholar
• Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013 Apr;107(4):608–615.
   PubMed Web of Science ®Google Scholar
• Kagiyama N, Takayanagi N, Kanauchi T, et al. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2(1):e000058.
   PubMedGoogle Scholar
• Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022 May 1;205(9):e18–e47.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Oct 31;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020 Sep;8(9):925–934.
   PubMed Web of Science ®Google Scholar
• Vonk MC, Walker UA, Volkmann ER, et al. Natural variability in the disease course of SSc-ILD: implications for treatment. Eur Respir Rev. 2021 Mar 31;30(159):200340.
   PubMed Web of Science ®Google Scholar
• Volkmann ER. Natural history of systemic sclerosis-related interstitial lung disease: how to identify a progressive fibrosing phenotype. J Scleroderma Relat Disord. 2020 Mar;5(2 Suppl):31–40.
   PubMed Web of Science ®Google Scholar
• Distler O, Assassi S, Cottin V, et al. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J. 2020 May;55(5):1902026.
   PubMed Web of Science ®Google Scholar
• Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1248–1254.
   PubMed Web of Science ®Google Scholar
• Wu W, Jordan S, Becker MO, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis. 2018 Sep;77(9):1326–1332.
   PubMed Web of Science ®Google Scholar
• Zamora-Legoff JA, Krause ML, Crowson CS, et al. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2017 Mar;69(3):542–549.
   PubMed Web of Science ®Google Scholar
• Rodríguez Portal JA, Brito García N, Díaz Del Campo Fontecha P, et al. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 1: epidemiología, factores de riesgo y pronóstico. Reumatol Clin. 2022; [en prensa].
   PubMedGoogle Scholar
• Morisset J, Vittinghoff E, Lee BY, et al. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med. 2017 Jun;127:51–56.
   PubMed Web of Science ®Google Scholar
• Nurmi HM, Purokivi MK, Karkkainen MS, et al. Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease? BMC Pulm Med. 2017 Jan 13;17(1):16.
   PubMedGoogle Scholar
• Trang G, Steele R, Baron M, et al. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int. 2012 Mar;32(3):645–653.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Kagouridis K, Papadaki G, et al. Treating CTDs related fibrotic ILDs by immunosuppressants: “facts and faults”. Lung. 2014 Apr;192(2):221–223.
   PubMed Web of Science ®Google Scholar
• Papiris SA, Kolilekas L, Kagouridis K, et al. ipf-acute exacerbations: advances and future perspectives. Front Pharmacol. 2022;13:836553.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655–2666.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep;4(9):708–719.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020 Mar 17;172(6):369–380.
   PubMed Web of Science ®Google Scholar
• Sparks JA, Dellaripa PF, Glynn RJ, et al. Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial. Arthritis Rheumatol. 2020 Dec;72(12):2065–2071.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Pradhan A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019 Feb 21;380(8):752–762.
   PubMed Web of Science ®Google Scholar
• Narváez J, Díaz Del Campo Fontecha P, Brito García N, et al. Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento. Reumatol Clin. 2022; [en prensa]
   Google Scholar
• Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2021 Feb;57(2):2000337.
   PubMed Web of Science ®Google Scholar
• Ibfelt EH, Jacobsen RK, Kopp TI, et al. Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study. Rheumatology (Oxford). 2021 Jan 5;60(1):346–352.
   PubMed Web of Science ®Google Scholar
• Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open. 2019 May 5;9(5):e028466.
   PubMed Web of Science ®Google Scholar
• Rojas-Serrano J, Herrera-Bringas D, Pérez-Roman DI, et al. Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol. 2017 July;36(7):1493–1500.
   PubMed Web of Science ®Google Scholar
• van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014 Jun 25;311(24):2490–2498.
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011 Aug 6;378(9790):498–506.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018 Jan 4;378(1):35–47.
   PubMed Web of Science ®Google Scholar
• Del Papa N, Onida F, Zaccara E, et al. Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis. Bone Marrow Transplant. 2017 Jan;52(1):53–58.
   PubMed Web of Science ®Google Scholar
• Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2021 July;73(7):1301–1310.
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 Oct;8(10):963–974.
   PubMed Web of Science ®Google Scholar
• Crespo MM, Lease ED, Sole A, et al. ISHLT consensus document on lung transplantation in patients with connective tissue disease: part I: epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. J Heart Lung Transplant. 2021 Nov;40(11):1251–1266.
   PubMed Web of Science ®Google Scholar
• Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017 Jun 15;18(1):275.
   PubMedGoogle Scholar
• Evaluation of efficacy and safety of rituximab with mycophenolate mofetil in patients with interstitial lung disease (EvER-ILD) [cited 2022 24 enero]. Available from: https://clinicaltrials.gov/ct2/show/NCT02990286
   Google Scholar
• April (Abatacept in Rheumatoid arthritis-ILD) [cited 2022 24 enero]. Available from: https://clinicaltrials.gov/ct2/show/NCT03084419
   Google Scholar
• Narváez J, Luch J, Molina-Molina M, et al. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum. 2020 Oct;50(5):977–987.
   PubMed Web of Science ®Google Scholar
• Narváez J, Robles-Pérez A, Molina-Molina M, et al. Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease. Semin Arthritis Rheum. 2020 Oct;50(5):902–910.
   PubMed Web of Science ®Google Scholar
• Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, et al. Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review. Autoimmun Rev. 2021 Jun;20(6):102830.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016 Sep;43(9):1672–1679.
   PubMed Web of Science ®Google Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 May;9(5):476–486.
   PubMed Web of Science ®Google Scholar
• Scleroderma Lung Study III - Combining Pirfenidone with Mycophenolate (SLSIII) [cited 2022 24 enero]. Available from: https://clinicaltrials.gov/ct2/show/NCT03221257
   Google Scholar
• Phase ll Study of Pirfenidone in Patients with RAILD (TRAIL1) [cited 2022 24 enero]. Available from: https://clinicaltrials.gov/ct2/show/NCT02808871
   Google Scholar
• Talotta R. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease. Immunotherapy. 2021 Feb;13(3):241–256.
   PubMed Web of Science ®Google Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA. 2018 Jun 12;319(22):2299–2307.
   PubMed Web of Science ®Google Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med. 2019 Aug;7(8):657–664.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020 Jan;8(1):25–33.
   PubMed Web of Science ®Google Scholar
• Maher TM, van der Aar EM, van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018 Aug;6(8):627–635.
   PubMed Web of Science ®Google Scholar